Theratechnologies Net Worth
Theratechnologies Net Worth Breakdown | THTX |
Theratechnologies Net Worth Analysis
Theratechnologies' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Theratechnologies' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Theratechnologies' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Theratechnologies' net worth analysis. One common approach is to calculate Theratechnologies' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Theratechnologies' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Theratechnologies' net worth. This approach calculates the present value of Theratechnologies' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Theratechnologies' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Theratechnologies' net worth. This involves comparing Theratechnologies' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Theratechnologies' net worth relative to its peers.
Enterprise Value |
|
To determine if Theratechnologies is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Theratechnologies' net worth research are outlined below:
| Theratechnologies may become a speculative penny stock | |
| Theratechnologies had very high historical volatility over the last 90 days | |
| Theratechnologies has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 81.76 M. Net Loss for the year was (23.96 M) with profit before overhead, payroll, taxes, and interest of 56.22 M. | |
| Theratechnologies currently holds about 36.46 M in cash with (5.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38. | |
| Latest headline from gurufocus.com: Theratechnologies Announces Resumed Production of EGRIFTA SV |
Theratechnologies uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Theratechnologies. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Theratechnologies' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 10th of April 2024 Next Financial Report | View | |
| 30th of November 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 31st of August 2023 Last Quarter Report | View | |
| 30th of November 2022 Last Financial Announcement | View |
Know Theratechnologies' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Theratechnologies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Theratechnologies backward and forwards among themselves. Theratechnologies' institutional investor refers to the entity that pools money to purchase Theratechnologies' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goss Wealth Management Llc | 2024-09-30 | 42.5 K | Citadel Advisors Llc | 2024-09-30 | 38.1 K | Summit Trail Advisors, Llc | 2024-09-30 | 33.1 K | Bare Financial Services Inc | 2024-09-30 | 26.8 K | Beacon Pointe Advisors, Llc | 2024-09-30 | 26.5 K | Geode Capital Management, Llc | 2024-09-30 | 25.7 K | Bank Of Montreal | 2024-09-30 | 18.2 K | Bmo Capital Markets Corp. | 2024-09-30 | 18.2 K | Kohmann Bosshard Financial Services, Llc | 2024-09-30 | 15.4 K | Soleus Capital Management, L.p. | 2024-09-30 | 4.8 M | Aigh Capital Management, Llc | 2024-09-30 | 3.7 M |
Follow Theratechnologies' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 61.33 M.Market Cap |
|
Project Theratechnologies' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.31) | (0.33) | |
| Return On Assets | (0.35) | (0.37) | |
| Return On Equity | 1.32 | 1.39 |
When accessing Theratechnologies' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Theratechnologies' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Theratechnologies' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Theratechnologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Theratechnologies. Check Theratechnologies' Beneish M Score to see the likelihood of Theratechnologies' management manipulating its earnings.
Evaluate Theratechnologies' management efficiency
Theratechnologies has return on total asset (ROA) of 0.1176 % which means that it generated a profit of $0.1176 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.1686) %, meaning that it created substantial loss on money invested by shareholders. Theratechnologies' management efficiency ratios could be used to measure how well Theratechnologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 1.39 in 2024, whereas Return On Tangible Assets are likely to drop (0.44) in 2024. At this time, Theratechnologies' Non Current Assets Total are fairly stable compared to the past year. Other Assets is likely to rise to about 2.2 M in 2024, whereas Total Assets are likely to drop slightly above 65.2 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.91) | (0.87) | |
| Tangible Book Value Per Share | (1.46) | (1.38) | |
| Enterprise Value Over EBITDA | (7.77) | (8.16) | |
| Price Book Value Ratio | (1.80) | (1.71) | |
| Enterprise Value Multiple | (7.77) | (8.16) | |
| Price Fair Value | (1.80) | (1.71) | |
| Enterprise Value | 59.9 M | 56.9 M |
Understanding the operational decisions made by Theratechnologies management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 0.9333 | Revenue 84.3 M | Quarterly Revenue Growth 0.084 | Revenue Per Share 1.865 | Return On Equity (11.17) |
Theratechnologies Earnings per Share Projection vs Actual
Theratechnologies Corporate Management
| LLB BA | VP Affairs | Profile | |
| H MSc | Vice Resources | Profile | |
| LLB LLM | General Secretary | Profile | |
| Elif McDonald | Director Relations | Profile | |
| Christian Marsolais | Senior Officer | Profile |
Additional Tools for Theratechnologies Stock Analysis
When running Theratechnologies' price analysis, check to measure Theratechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theratechnologies is operating at the current time. Most of Theratechnologies' value examination focuses on studying past and present price action to predict the probability of Theratechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theratechnologies' price. Additionally, you may evaluate how the addition of Theratechnologies to your portfolios can decrease your overall portfolio volatility.